Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation.

被引：2
|
作者：
Piha-Paul, Sarina Anne
Fu, Siqing
Hong, David S.
Janku, Filip
Karp, Daniel D.
Naing, Aung
Pant, Shubham
Ahnert, Jordi Rodon
Subbiah, Vivek
Tsimberidou, Apostolia Maria
Yap, Timothy Anthony
Meric-Bernstam, Funda
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
[3] Vall Hebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2611
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Simultaneous Expression of EGFR, HER2, HER3 and HER4 in Non-Small Cell Lung Cancer NSCLC: Correlation With Clinical Outcome and a Comparison Between Immunohistochemical Protein Expression and Silver In Situ Hybridization (SISH) For Detection of HER2 Gene Amplification
    Al-Saad, S.
    Al-Shibli, K.
    Donnem, T.
    Andersen, S.
    Bremnes, R. M.
    Busund, L. T.
    APMIS, 2010, 118 (03) : 245 - 246
  • [22] Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).
    Lee, Kyoungmin
    Lee, Kyung-Hun
    Kim, Dong-Wan
    Yoon, Jeesun
    Choi, Wonyoung
    Lee, Youngjoo
    Choi, Yoon Ji
    Lee, Soohyeon
    Kim, Ju Won
    Ryu, Hyewon
    Koo, Dong-Hoe
    Lee, Yun-Gyoo
    Jeung, Hei-Cheul
    Lee, Min-Young
    Lee, Namsu
    Kang, Myoung Joo
    Lee, Ji Eun
    Hong, Sook Hee
    Kang, Eun Joo
    Park, Inhae
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy or PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent gliobiastoma with EGFR amplification or presence of EGFRvIII mutation.
    Manuel Sepulveda, Juan
    Angeles Vaz, M.
    Hernandez-Lain, Aurelio
    Gil, Miquel
    Sanhez, Pilar
    Ana, Ramos
    Gallego, Oscar
    Reynes, Gaspar
    Victoria Bolos, Maria
    Luque, Raquel
    Quindos, M.
    Martinez Garcia, Maria
    Perez Segura, Pedro
    Benavides, Manuel
    Balana, Carmen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Shao Zhimin
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Yang, Haiyuan
    Li, Miao
    Xiang, Xiao
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation
    Sepulveda, J. M.
    Vaz, M. A.
    Gil, M.
    Reynes, G.
    Gallego, O.
    Bolos, M. V.
    Hernandez Lain, A.
    Sanchez-Gomez, P.
    Martinez, M.
    Vicente, E.
    Quindos, M.
    Luque, R.
    Ramos, A.
    Ruano, Y.
    Manneh, R.
    Perez Segura, P.
    Benavides, M.
    Balana, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S585 - S585
  • [26] Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
    Gao, Guanghui
    Li, Xingya
    Wang, Qiming
    Zhang, Yiping
    Chen, Jianhua
    Shu, Yongqian
    Hu, Yanping
    Fan, Yun
    Fang, Jian
    Chen, Gongyan
    Zhao, Jun
    He, Jianxing
    Wu, Fengying
    Zou, Jianjun
    Zhu, Xiaoyu
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer
    Zhang, Tongtong
    Li, Qing
    Chen, Shanshan
    Luo, Yang
    Fan, Ying
    Xu, Binghe
    ONCOTARGET, 2017, 8 (22) : 36750 - 36760
  • [28] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [29] A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
    Richards, Donald A.
    Braiteh, Fadi S.
    Anthony, Stephen Patrick
    Edenfield, Jeff
    Hellerstedt, Beth A.
    Raju, Robert N.
    Conkling, Paul
    Smith, David A.
    Becerra, Carlos
    Cohn, Allen Lee
    Denlinger, Crystal Shereen
    Garbo, Lawrence E.
    Wu, Hillary H.
    Garcia, Agustin
    McDonagh, Charlotte
    Frye, Sasha
    Agresta, Samuel V.
    Moyo, Victor M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
    Zheng, Jie
    Wang, Huan
    Yao, Jia
    Zou, Xianjin
    PHARMAZIE, 2014, 69 (01): : 38 - 42
12345